BACKGROUND: BI 695501 has demonstrated bioequivalence to both the US-licensed and EU-approved adalimumab reference product (RP) in rheumatoid arthritis. The aim of this head-to-head trial...
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States;
2 Eli Lilly and Company, Indianapolis, Indiana, United States;
3 University of Oxford, Oxford, United Kingdom...
1 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois, United States;
2 Eli Lilly and Company, Indianapolis, Indiana, United States;
3 University of Oxford...
1 Nancy University Hospital, Vandoeuvre-les-Nancy, France;
2 GI Alliance, United States;
3 Icahn School of Medicine at Mount Sinai, New York, United States;
4 UNIMI, Department of Pathoph...
1 University Hospital CHU of Liège, Liège, Belgium, Liège, Belgium;
2 University of Calgary, Calgary, Alberta, Canada;
3 Barts Health NHS Trust, London, United Kingdom;
4 NGERE, Faculty o...